These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16548769)

  • 1. Glycogen synthase kinase-3--a promising therapeutic target: Dr Hagit Eldar-Finkelman interviewed by Emma Quigley.
    Eldar-Finkelman H
    Expert Opin Ther Targets; 2006 Apr; 10(2):199-201. PubMed ID: 16548769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of vasoactive intestinal peptide in neuroprotection: Professor Illana Gozes is interviewed by Emma Quigley.
    Gozes I
    Expert Opin Ther Targets; 2007 Jun; 11(6):733-6. PubMed ID: 17504011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Science Signaling Podcast for 15 November 2016: A new type of kinase inhibitor.
    Eldar-Finkelman H; VanHook AM
    Sci Signal; 2016 Nov; 9(454):c22. PubMed ID: 27902446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The therapeutic potential of CD39: interview with Dr Simon Robson by Emma Quigley.
    Robson S
    Expert Opin Ther Targets; 2006 Oct; 10(5):649-52. PubMed ID: 16981822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycogen synthase kinase-3 as drug target: from wallflower to center of attention.
    Van Wauwe J; Haefner B
    Drug News Perspect; 2003 Nov; 16(9):557-65. PubMed ID: 14702136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment.
    Eldar-Finkelman H; Ilouz R
    Expert Opin Investig Drugs; 2003 Sep; 12(9):1511-9. PubMed ID: 12943495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders.
    Woodgett JR
    Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):281-90. PubMed ID: 14683459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting glycogen synthase kinase-3 in insulin signalling.
    Frame S; Zheleva D
    Expert Opin Ther Targets; 2006 Jun; 10(3):429-44. PubMed ID: 16706683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes.
    Kaidanovich O; Eldar-Finkelman H
    Expert Opin Ther Targets; 2002 Oct; 6(5):555-61. PubMed ID: 12387679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders.
    Gould TD; Picchini AM; Einat H; Manji HK
    Curr Drug Targets; 2006 Nov; 7(11):1399-409. PubMed ID: 17100580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.
    Medina M; Avila J
    Curr Pharm Des; 2010; 16(25):2790-8. PubMed ID: 20698823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions.
    Saraswati AP; Ali Hussaini SM; Krishna NH; Babu BN; Kamal A
    Eur J Med Chem; 2018 Jan; 144():843-858. PubMed ID: 29306837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta.
    Miyashita K; Nakada M; Shakoori A; Ishigaki Y; Shimasaki T; Motoo Y; Kawakami K; Minamoto T
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1114-22. PubMed ID: 19925395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease.
    Huang HC; Klein PS
    Curr Drug Targets; 2006 Nov; 7(11):1389-97. PubMed ID: 17100579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic.
    Medina M; Castro A
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):533-43. PubMed ID: 18600569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].
    Liu SN; Shen ZF
    Yao Xue Xue Bao; 2007 Dec; 42(12):1227-31. PubMed ID: 18338632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.
    Dobrić I
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):344-348. PubMed ID: 30665489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substrate competitive GSK-3 inhibitors - strategy and implications.
    Eldar-Finkelman H; Licht-Murava A; Pietrokovski S; Eisenstein M
    Biochim Biophys Acta; 2010 Mar; 1804(3):598-603. PubMed ID: 19770076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell adhesion molecules as therapeutic targets: interview with Professor Michael P Schön. Interviewed by Emma Quigley.
    Schön MP
    Expert Opin Ther Targets; 2006 Dec; 10(6):799-802. PubMed ID: 17105368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).
    Palomo V; Martinez A
    Expert Opin Ther Pat; 2017 Jun; 27(6):657-666. PubMed ID: 27828716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.